En el mes de la concesión de los Premios Nobel, rendimos homenaje a Alfred Nobel y a los galardonados con el Premio de Fisiología y Medicina de 2020

Francisco J. Sánchez-Muniz; Jesús M Culebras; Luis Vicente-Vacas

doi:10.19230/jonnpr.4028

Autores/as

Francisco J. Sánchez-Muniz Catedrático Emérito de Nutrición. Facultad de Farmacia de la Universidad Complutense de Madrid y Académico de número de la Real Academia Nacional de Farmacia, España https://orcid.org/0000-0002-2660-5126
Jesús M Culebras De la Real Academia de Medicina de Valladolid y del IBIOMED, Universidad de León. Miembro de Número y de Honor de la Academia Española de Nutrición y Dietética. Académico Asociado al Instituto de España. AcProfesor Titular de Cirugía. Director, Journal of Negative & No Positive Results. Director Emérito de NUTRICION HOSPITALARIA, España https://orcid.org/0000-0003-3234-6957
Luis Vicente-Vacas Editor de Journal of Negative & No Positive Results. España https://orcid.org/0000-0002-4701-4149

DOI:

https://doi.org/10.19230/jonnpr.4028

Resumen

-

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Sánchez-Muniz FJ, Culebras JM, Vicente-Vacas L. In the month of the Nobel Prize Awards, we pay tribute to Alfred Nobel and to the recipients of the 2017 Prize in Physiology and Medicine. JONNPR 2017; 2(11): 577-580.

Sánchez-Muniz FJ, Culebras JM, Vicente-Vacas L. In the month of the Nobel Prize Awards, we pay tribute to Alfred Nobel and to the recipients of the 2018 Prize in Physiology and Medicine. JONNPR 2018; 3(11): 857-665.

Sánchez-Muniz FJ, Culebras JM, Vicente-Vacas L. We pay tribute to Alfred Nobel and to the recipients of the 2019 Prize in Physiology and Medicine. JONNPR. 2020;5(3):236-45. DOI: 10.19230/jonnpr.3451

Premio Nobel de Medicina 2020: Página Oficial. https://www.nobelprizemedicine.org/the-nobel-prize-in- physiology-or-medicine-2020/

Rincón del vago https://www.rincondelvago.com/informacion/premios-nobel/

Nobel de Medicina por investigación celular - BBC News Mundowww.bbc.com › 2009/10 › 091005_nobel_medicina_jp

https://www.google.es/search?newwindow=1&client=firefoxb&dcr=0&tbm=isch&sa=1&q=Fotos+de+Alfred+Nobel+&oq

Flexner A. La utilidad de los conocimientos útiles. En: La utilidad de lo inútil. Manifiesto. Ordina N (ed.). Acantilado, Barcelona, 2013; pp153-171.

Ehrlich P. www.historiadelamedicina.org

Research Update, june 9, 2016. Story of discovery: hepatitis C: from non-A, non-B hepatitis to cure.

Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200:365–373.

Blumberg BS, Alter HJ, Visnich S. A ‘‘new’’ antigen in leukemia sera. JAMA 1965;191:541–546.

Krugman S, Giles JP. Viral hepatitis. New light on an old disease. JAMA 1970;212:1019–1029.

Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 1968;60:814–821.

Gocke DJ. A prospective study of posttransfusion hepatitis. The role of Australia antigen. JAMA 1972;219:1165– 1170.

Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691–699.

Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439–462.

Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575–1578.

Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62 j:S87–S99.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–1492.

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426–1432.

Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103–107.

Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351–1358.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164–171.

Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–221.

Bourlière M, Sulkowski MS, Omata M, Zeuzem S, Feld JJ, Lawitz E, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 2014;60:239A.

Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:320A.

Reddy RK, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with posttransplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014;60:200A.